Literature DB >> 20186025

A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage.

Sara de Cabanyes Candela1, Frank C Detterbeck.   

Abstract

BACKGROUND: Many clinicians use restaging after induction therapy as a way to select patients for surgery.
METHODS: A systematic review was conducted to define the reliability of restaging tests after induction therapy for stage III(N2) lung cancer, when compared with pathologic findings at surgery.
RESULTS: A complete response at all sites carries a false-negative (FN) rate of 50% for computed tomography and 30% for positron emission tomography. Mediastinal node involvement has FN and false-positive rates of 33% and 33% by computed tomography, and 25% and 33% by positron emission tomography. The FN rate of invasive restaging is 22% by repeat mediastinoscopy, 14% by esophageal ultrasound and needle aspiration in expert hands (reliable results are not yet available for endobronchial ultrasound), and 9% by primary mediastinoscopy done with optimal thoroughness. These results are not significantly affected by the type of induction therapy or the timing of restaging.
CONCLUSION: The ability to identify patients who have achieved mediastinal downstaging other than by a careful primary mediastinoscopy is poor.

Entities:  

Mesh:

Year:  2010        PMID: 20186025     DOI: 10.1097/JTO.0b013e3181ce3e5e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

Review 1.  Current status and perspective of EBUS-TBNA.

Authors:  Takahiro Nakajima; Kazuhiro Yasufuku; Ichiro Yoshino
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-02-26

Review 2.  The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer.

Authors:  Katarzyna Czarnecka-Kujawa; Kazuhiro Yasufuku
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 3.  The use and misuse of positron emission tomography in lung cancer evaluation.

Authors:  Ching-Fei Chang; Afshin Rashtian; Michael K Gould
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

4.  Perspectives on the effect of nodal downstaging and its implication of the role of surgery in stage IIIA (N2) non-small cell lung cancer.

Authors:  Linda W Martin; Reza J Mehran
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 5.  Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions.

Authors:  Carmen Vallejo Ocańa; Pilar Garrido López; Ignacio Muguruza Trueba
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

6.  Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.

Authors:  D Marquez-Medina; A Martin-Marco; S Popat
Journal:  Clin Transl Oncol       Date:  2015-07-24       Impact factor: 3.405

7.  Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.

Authors:  R Taylor Ripley; Kei Suzuki; Kay See Tan; Prasad S Adusumilli; James Huang; Bernard J Park; Robert J Downey; Nabil P Rizk; Valerie W Rusch; Manjit Bains; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

8.  Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.

Authors:  Waldemar Schreiner; Sofiya Gavrychenkova; Wojciech Dudek; Ralf Joachim Rieker; Sebastian Lettmaier; Rainer Fietkau; Horia Sirbu
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

9.  Radiotherapy Planning and Molecular Imaging in Lung Cancer.

Authors:  Angelina Filice; Massimiliano Casali; Patrizia Ciammella; Marco Galaverni; Federica Fioroni; Cinzia Iotti; Annibale Versari
Journal:  Curr Radiopharm       Date:  2020

10.  A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.

Authors:  Chao Lv; Yuanyuan Ma; Nan Wu; Shi Yan; Qingfeng Zheng; Yu Sun; Shaolei Li; Jian Fang; Yue Yang
Journal:  World J Surg Oncol       Date:  2013-03-21       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.